Agoracom Blog Home

Posts Tagged ‘CardiolRx’

VIDEO – Cardiol Therapeutics $CRDL Sees Accelerated Growth with NASDAQ Uplisting & Continued COVID-19 Threat $LXRX $MESO $HGEN $TYNA

Posted by AGORACOM-AB at 12:15 PM on Monday, August 16th, 2021

Biotech companies, by their very nature, can often be difficult to understand for investors… but in order to understand Cardiol, all you have to know is that the firm is developing therapies for heart disease and heart failure through cannabidiols.  

Cardiol Therapeutics is a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (heart/blood vessels).

  • The company has received approval from the U.S. FDA to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™.
  • CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically producedmanufactured under cGMP and THC free. (less than 10 ppm)

Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, most common cause of sudden cardiac death in people under 35.

This week, the company passed another major milestone, moving from the OTC Markets to a U.S. listing on NASDAQ, under the symbol $CRDL – the same as its TSX symbol.

And with the COVID-19 Delta Variant running rampant through North America, Cardiol’s work has become more important than ever.

We sat down with David Elsley, Cardiol Therapeutics’ President & CEO, to discuss the uplisting…

VIDEO – Cardiol Therapeutics $CRDL.ca $CRTPF lands $22m Boost to CardiolRx War Chest, Eyes Explosive Growth in Cannabidiol Sector

Posted by AGORACOM-AB at 2:29 PM on Tuesday, May 18th, 2021

Biotech companies, by their very nature, can often be difficult to understand for investors… but in order to understand Cardiol, all you have to know is that the firm is developing therapies for heart disease and heart failure through cannabidiols.  

Cardiol Therapeutics is a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (heart/blood vessels).

  • The company has received approval from the U.S. FDA to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™.
  • CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically producedmanufactured under cGMP and THC free. (less than 10 ppm)

Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, most common cause of sudden cardiac death in people under 35.

The company gained a huge boost this month closing its “bought deal” short form prospectus offering for aggregate gross proceeds of approximately $22m. This came after upsizing from the previously announced $15m offering; and after receiving more than $10m earlier this year from the exercise of warrants and stock options.

So, the company now sits on an enviable war chest. And it has ambitious plans for the future.

David Elsley, Cardiol Therapeutics’ President & CEO, walks us through them…

VIDEO – Cardiol Therapeutics $CRDL.ca $CRTPF is a Clinical-Stage Biotech Firm taking on the $30BN Heart Disease Healthcare Market via Cannabidiols and Cutting-Edge Anti-Inflammatory Therapies

Posted by AGORACOM-JC at 4:23 PM on Thursday, April 22nd, 2021

Cardiol Therapeutics $CRDL.ca $CRTPF is a groundbreaking, clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (heart/blood vessels).

  • The company has received approval from the U.S. FDA to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™, in treating hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD).
  • CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP and THC free.

Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, most common cause of sudden cardiac death in people under 35.

The company is also developing proprietary cannabidiol formulations for the treatment of chronic heart failure.

One such key development is its commercial product, Cortalex™, an extra-strength formulation (100 mg/mL concentration) of cannabidiol oil that is pharmaceutically produced to be free of THC. Cardiol believes Cortalex™ to be the purest form of cannabidiol oil available in Canada.

It is the first THC-free extra-strength formulation of cannabidiol oil available across Canada exclusively online at Medical Cannabis by Canada’s largest pharmacy retailer, Shoppers Drugs Mart.

  • In March 2020, Cardiol signed a supplier agreement to become a medical cannabidiol supplier to Shoppers Drug Mart. The retailer will supply Cardiol’s pharmaceutical cannabidiol products to Shoppers for sale in all provinces and territories in Canada through Shoppers’ online store, Medical Cannabis by Shoppers.

And there’s plenty more to write home about:

  • ~ $27M from exercise of warrants + equity raise since June 2020
  • Uplisting to NASDAQ
  • Team expansion with Chief Medical Officer hire

David Elsley, Cardiol Therapeutics’ President & CEO, gives us the low-down. Check it out: